High-dose piracetam is effective on cerebellar ataxia in a patient with cerebellar cortical atrophy

Movement Disorders

Volumn 18, Issue 4, 2003, Pages 457-459

  Vural, Melih ^a   Özekmekçi, Sibel ^a   Apaydin, Hülya ^a   Altinel, Attila ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cerebellar ataxia; Piracetam; Tandem gait; Treatment of ataxia

Indexed keywords

PIRACETAM; PLACEBO;

ADULT; ARTICLE; CASE REPORT; CEREBELLAR ATAXIA; CEREBELLUM ATROPHY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; GAIT DISORDER; HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ADULT; ATROPHY; CEREBELLAR ATAXIA; CEREBELLAR CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; PIRACETAM; SINGLE-BLIND METHOD; SPINOCEREBELLAR DEGENERATIONS; TREATMENT OUTCOME; WALKING;

EID: 0038746971     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10364     Document Type: Article

References (22)

1. Trouillas P, Xie J, Getenet JC, et al. Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication. Rev Neurol 1995;151:708-713.
2. Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol 1995;52:982-988.
3. Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Arch Neurol 1997;54:749-752.
4. Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord 1997;12:613-614.
5. Svetel M, Vojvodic N, Filipovic SR, Dragasevic N, Sternic N, Kostic VS. Buspirone in the treatment of cerebellar ataxia. Srp Arh Celok Lek 1999;127:312-315.
6. Megna J, O'Dell M. Ataxia from lithium toxicity successfully treated with high-dose buspirone: a single-case experimental design. Arch Phys Med Rehabil 2001;82:1145-1148.
7. Botez MI, Botez-Marquard T, Elie R, Pedraza OL, Goyette K, Lalonde R. Amantadine hydrochloride treatment in heredodegenerative ataxias: a double-blind study. J Neurol Neurosurg Psychiatry 1996;61:259-264.
8. Peterson PL, Saad J, Nigro MA. The treatment of Friedreich's ataxia with amantadine hydrochloride. Neurology 1988;38:1478-1480.
9. Filla A, De Michele G, Orefice G, et al. A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can J Neurol Sci 1993;20:52-55.
10. Strubbe JH, Cyprisiak E. Dérivés de l'acide (2-Oxo-Pyrrolidine) acétique. Rev Indust Chim Belge 1967;32:112.
11. Pepeu G, Spignoli G. Neurochemical actions of "nootropic drugs." Adv Neurol 1990;51:247-252.
12. Croisile B, Trilled M, Fondarai J, Laurent B, Mauguiere F, Billardon M. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993;43:301-305.
13. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spastisity. II. General and regional treatments. Muscle Nerve 1997(Suppl. 6):S92-S120.
14. Terwinghe G, Daumerie J, Nicaise C, Rosillon O. Effect therapeutique du piracetam dans un cas de myoclonies d'action post-anoxique. Acta Neurol Belg 1978;78:30-36.
15. Cremieux C, Serratrice G. Myoclonies d'intention et d'action postanoxiques: amelioration par le piracetam. Nouv Press Med 1979;41:3357-3358.
16. Obeso JA, Artieda J, Rothwell JC, Day B, Thompson P, Marsden CD. The treatment of severe action myoclonus. Brain 1989; 112: 765-767.
17. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993;8:63-68.
18. Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys CH. Platelet anti-aggregant and rheological properties of piracetam. Arzneimittelforschung 1993;43:110-118.
19. Ikeda A, Shibasaki H, Tashiro K, Mizuno Y, Kimura J, and the Myoclonus/Piracetam Study Group. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. Mov Disord 1996;11:691-700.
20. Vial H, Claustre Y, Pacheco H. Effects de substances stimulantes, sedatives, et hypnotiques sur les taux d'aminoacides cerebrales libres chez le rat. J Pharmacol 1974;5:461-478.
21. Tacconi MT, Wirtman RJ. Piracetam: physiological disposition and mechanism of action. Adv Neurol 1986;43:675-685.
22. Currier RD. A treatment for ataxia [editorial]. Arch Neurol 1995; 52:449.